Single-center and randomized comparison clinical trial of modified Qingqi Huatan Decoction for treating cough with phlegm-heat stagnated in lung syndrome
Objective:To evaluate the effectiveness and safety of modified Qingqi Huatan Decoction in treating cough with phlegm-heat stagnated in lung syndrome.Methods:A single-center and randomized comparison trial design was used,and a total of 85 patients were included,including 43 in the control group and 42 in the observation group.Patients in the control group were given conventional Western medicine treatment,and patients in the observation group took modified Qingqi Huatan Decoction orally on the treatment basis of the control group for 7 days.The efficacy and safety were evaluated from the aspects of clinical efficacy,TCM symptom score,cough symptom score,inflammation index and adverse reactions.Results:The clinical effective rate of the observation group was higher than that of the control group.The scores of main symptoms such as cough,expectoration,wheeze,chest distress and secondary symptoms such as fever,rale,constipation,dry mouth,thirst and desire to drink,total TCM symptom score,white blood cell count(WBC),neutrophil percentage(NEP),C-reactive protein(CRP)and serum amyloid protein(SAA)levels were all lower than those of the control group,with statistical significances(P<0.05,P<0.01).No adverse reactions related to treatment drugs were found.Conclusion:Modified Qingqi Huatan Decoction can improve the clinical symptoms of patients with cough with phlegm-heat stagnated in lung syndrome,reduce inflammatory response,and is safe in clinical application.
万方数据
维普
